HARROW, INC.(HROW)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,101 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in HROW
Events flagged as statistical outliers against HROW's own multi-year baseline — not fixed dollar thresholds.
HROW Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for HARROW, INC. (HROW), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores HROW at 40.5/100 on a 32-signal composite quality model, placing it at rank #2,101 of 2,962 stocks — the bottom half of the AI-ranked universe. HROW scores in the top quartile across revenue growth (89.6). Areas of concern include profitability (16.4) and balance sheet strength (17.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), HARROW, INC. reports quarterly revenue of $70.7M, net income of $-17.3M, free cash flow of $-10.2M. Top institutional holders of HROW by reported 13-F value include BlackRock, Opaleye Management, Private Capital Management, based on the most recent SEC filings. HROW trades on the Nasdaq exchange and files with the SEC under CIK 1360214. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate HROW daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for HARROW, INC. directly from SEC EDGAR. HARROW, INC.'s 13F Pro composite quality score has ranged between 30 and 61 since 2021, currently 40.5 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$70.7M
Net Income
Q2 2026
$-17.3M
Free Cash Flow
Q2 2026
$-10.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+36.4% YoYNet Income
+70.6% YoYOperating Income
+245.9% YoYEPS (Diluted)
+71.4% YoYTotal Assets
+2.7% YoYTotal Debt
-4.8% YoYOp. Cash Flow
+297.6% YoYFree Cash Flow
+280.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $272.3M +36.4% | $199.6M +53.3% | $130.2M +47.0% | $88.6M +22.2% | $72.5M +48.3% | $48.9M |
| Net Income | $-5.1M +70.6% | $-17.5M +28.4% | $-24.4M -73.3% | $-14.1M +21.8% | $-18.0M -436.4% | $-3.4M |
| Operating Income | $30.5M +245.9% | $8.8M +1946.9% | $431.0K -77.5% | $1.9M +18.9% | $1.6M +319.2% | $385.0K |
| EPS (Diluted) | $-0.14 +71.4% | $-0.49 +34.7% | $-0.75 -47.1% | $-0.51 | — | $-0.13 |
| Total Assets | $399.5M +2.7% | $389.0M +24.6% | $312.2M +98.4% | $157.4M +60.1% | $98.3M +71.1% | $57.5M |
| Total Debt | $250.0M -4.8% | $262.7M +6.5% | $246.7M +62.6% | $151.8M +47.3% | $103.0M +415.0% | $20.0M |
| Operating Cash Flow | $43.9M +297.6% | $-22.2M -678.2% | $3.8M +125.2% | $1.7M -66.5% | $5.1M +562.0% | $-1.1M |
| Free Cash Flow | $43.0M +280.6% | $-23.8M -1099.9% | $2.4M +366.8% | $-892.0K -127.1% | $3.3M +268.0% | $-2.0M |
Get alerted when HROW's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for HARROW, INC. including:
Top Institutional Holders of HROW
BlackRock, Inc.
$116.4M2,740,117 shOpaleye Management Inc.
$101.9M2,400,000 shPrivate Capital Management, LLC
$67.9M1,598,770 shVANGUARD CAPITAL MANAGEMENT LLC
$60.2M1,417,212 shDeep Track Capital, LP
$41.2M969,000 shSTATE STREET CORP
$39.9M939,888 shGEODE CAPITAL MANAGEMENT, LLC
$38.5M905,560 shBAMCO INC /NY/
$34.4M809,350 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$31.6M742,900 shDIMENSIONAL FUND ADVISORS LP
$28.3M667,036 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $116.4M | 2,740,117 |
| Opaleye Management Inc. | $101.9M | 2,400,000 |
| Private Capital Management, LLC | $67.9M | 1,598,770 |
| VANGUARD CAPITAL MANAGEMENT LLC | $60.2M | 1,417,212 |
| Deep Track Capital, LP | $41.2M | 969,000 |
| STATE STREET CORP | $39.9M | 939,888 |
| GEODE CAPITAL MANAGEMENT, LLC | $38.5M | 905,560 |
| BAMCO INC /NY/ | $34.4M | 809,350 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31.6M | 742,900 |
| DIMENSIONAL FUND ADVISORS LP | $28.3M | 667,036 |
Companies Similar to HROW
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Axogen, Inc.
BIODESIX INC
Tarsus Pharmaceuticals, Inc.
SUPERNUS PHARMACEUTICALS, INC.
Phathom Pharmaceuticals, Inc.
Alphatec Holdings, Inc.
Journey Medical Corp
ARDELYX, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put HROW on your watchlist
Track score changes the day HARROW, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is HROW a good stock to buy?
13F Pro's AI-powered analysis of HARROW, INC. (HROW) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for HROW are available on the HROW stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. HROW is classified as a small company.
Which hedge funds own HROW?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling HROW. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of HARROW, INC.'s investment landscape.